Clinical Trials on V600-mutated BRAF Unresectable Melanoma
Total 201 results
-
Daiichi Sankyo, Inc.PlexxikonTerminatedV600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF InhibitorUnited States, Germany, France
-
Novartis PharmaceuticalsCompletedBRAF v600 Mutated Metastatic MelanomaUnited States
-
Pierre Fabre MedicamentCompletedMelanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLCChina
-
Pierre Fabre MedicamentBiotrialActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationFrance
-
Pierre Fabre MedicamentBiotrialCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationFrance
-
Assistance Publique - Hôpitaux de ParisUnknownMelanoma BRAF V600E/K Mutated | CDNKN2A Loss DefinedFrance
-
Fore BiotherapeuticsActive, not recruitingAdvanced Unresectable Solid Tumors | BRAF-mutated TumorsUnited States
-
Mohammed M MilhemGenentech, Inc.TerminatedMelanoma | Metastatic Melanoma | BRAF-mutated Metastatic Melanoma | V600EBRAF-mutated Metastatic MelanomaUnited States
-
Pierre Fabre MedicamentWithdrawnHepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 MutationSpain, Czechia, Italy
-
Pierre Fabre MedicamentRecruitingMetastatic Melanoma | Melanoma (Skin) | BRAF V600 MutationPortugal
-
H. Lee Moffitt Cancer Center and Research InstitutePfizerRecruitingMelanoma Stage IV | BRAF V600 Mutation | Melanoma Stage IIIUnited States
-
University Hospital TuebingenTerminatedMetastatic Melanoma (Carrying BRAF V600 Mutation)Germany
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Solid Neoplasm | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma... and other conditionsUnited States
-
Genentech, Inc.CompletedMetastatic Melanoma, BRAF V600 Mutation PositiveKorea, Republic of, Russian Federation, Israel, United States
-
MelanomaPRO, RussiaCrocus Medical B.V.CompletedBRAF V600 Mutation | Cutaneous Melanoma, Stage IVRussian Federation
-
Novartis PharmaceuticalsRecruitingRare Unresectable or Metastatic BRAF V600E Mutation-positive Solid TumorsUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7United States
-
Dr. Ronnie ShapiraNot yet recruitingMetastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
-
Regina Elena Cancer InstituteRecruitingMelanoma (Skin) | Liquid Biopsy | Melanoma Stage IV | Melanoma Stage III | BRAF V600EItaly
-
Intergruppo Melanoma ItalianoActive, not recruiting
-
UNC Lineberger Comprehensive Cancer CenterGlaxoSmithKlineCompletedUnresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant MelanomaUnited States
-
PfizerTerminatedMetastatic Pancreatic Adenocarcinoma | BRAF Mutated MelanomaUnited States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
-
Eisai Inc.TerminatedUnresectable Stage III Melanoma | Wild Type BRAF Stage IV MelanomaUnited States
-
West China HospitalRecruitingBRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Vemurafenib (BRAFi) Plus Cetuximab (EGFRi) Combined With PD-1 Monoclonal AntibodyChina
-
AIO-Studien-gGmbHUniversitätsklinikum Hamburg-Eppendorf; Merck Serono GmbH, Germany; Pierre Fabre...RecruitingColorectal Cancer | Colon Cancer | BRAF V600 Mutation | BRAF V600E | Localized CancerGermany
-
PfizerCompletedSolid Tumors Harboring a BRAF V600 MutationUnited States, France, Italy, Singapore, Australia, Spain, Switzerland, Canada, Belgium
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsRecruitingBRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid TumorJapan
-
ABM Therapeutics Shanghai Company LimitedRecruitingAdvanced Solid Tumor | BRAF V600 MutationChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); PfizerTerminatedGlioblastoma | High Grade Glioma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Pleomorphic Xanthoastrocytoma | BRAF V600E | BRAF V600KUnited States
-
Technische Universität DresdenTerminatedBrain Metastases | Malignant Melanoma Stage IV | BRAF V600 MutationGermany
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial MelanomaUnited States
-
University of California, San FranciscoNovartisCompletedBRAF Mutant Metastatic MelanomaUnited States
-
Novartis PharmaceuticalsCompletedBRAF-positive Metastatic MelanomaUnited States
-
Deciphera Pharmaceuticals LLCNot yet recruitingMelanoma | Non-Small Cell Lung Cancer | Advanced Solid Tumor | Pancreatic Ductal Adenocarcinoma | BRAF Gene Mutation | RAS Mutation | NF1 Mutation | RAF Mutation | CRAF Gene MutationUnited States
-
UNICANCERMerck Sharp & Dohme LLC; Pierre Fabre Medicament; European Association of Dermato...RecruitingBrain Metastases | Malignant Melanoma | BRAF V600 MutationFrance
-
Abramson Cancer Center of the University of PennsylvaniaCompletedAdvanced BRAF Mutant MelanomaUnited States
-
PfizerCompletedBRAF or NRAS Mutant Metastatic MelanomaUnited States, Netherlands, Italy, Germany, Switzerland
-
Piramal Enterprises LimitedMelanoma Research Foundation Breakthrough ConsortiumSuspendedAdvanced or Inoperable Malignant Melanoma With BRAF MutationUnited States
-
Array BioPharmaTerminatedLocally Advanced Metastatic BRAF Mutant MelanomaAustralia, Canada, Netherlands, United States
-
Regeneron PharmaceuticalsBristol-Myers SquibbCompletedMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Regeneron PharmaceuticalsBristol-Myers SquibbActive, not recruitingMelanoma | Metastatic Melanoma | Unresectable Melanoma | Advanced MelanomaUnited States
-
Novartis PharmaceuticalsCompletedBRAF Positive Metastatic MelanomaUnited States
-
Bristol-Myers SquibbCompletedMetastatic Melanoma | Unresectable MelanomaUnited States, France
-
Yana NajjarBristol-Myers Squibb; PfizerActive, not recruitingUnresectable Melanoma | Advanced MelanomaUnited States
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruiting
-
University of California, IrvineGlaxoSmithKlineCompletedUnresectable Melanoma | Stage IV Melanoma | Stage III MelanomaUnited States
-
Dana-Farber Cancer InstitutePartner Therapeutics (PTx)WithdrawnMetastatic Melanoma | Unresectable Melanoma | Stage IV Melanoma | Stage III MelanomaUnited States
-
Elizabeth Buchbinder, MDGenentech, Inc.RecruitingStage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous MelanomaUnited States
-
Jill M KolesarNational Cancer Institute (NCI); NovartisRecruitingMetastatic Melanoma | BRAF Gene MutationUnited States